




10/069623
JC10 Rec'd PCT/PTO 26 FEB 2002

Certificate of Mailing		
Date of Deposit <u>February 26, 2002</u>		Label Number: <u>EV 040972097 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.		
<u>Guy E. Beardsley</u> Printed name of person mailing correspondence		 Signature of person mailing correspondence
Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		Attorney's Docket Number: <u>06727/010002</u> U.S. Application Number: <u>PCT/US00/24129</u>
INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US00/24129	September 1, 2000	September 2, 1999
TITLE OF INVENTION:	USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS	
APPLICANTS FOR DO/EO/US:	Robert A. Murgita, Robert Mulroy, and Stace Lindsay	
Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.	
3.	<input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(1).	
4.	<input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.	
5.	A copy of the International Application as filed (35 U.S.C. § 371(c)(2)). <input checked="" type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. is not required, as the application was filed with the United States Receiving Office (RO/US).	
6.	<input type="checkbox"/> A translation of the International Application into English (35 U.S.C. § 371(c)(2)).	
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)). <input type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> d. have not been made and will not be made.	
8.	<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)).	
10.	<input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)).	
11.	<input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98.	
12.	<input type="checkbox"/> An assignment for recording. A separate cover sheet in compliance with 37 §§ 3.28 and 3.31 is included.	
13.	<input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.	
14.	<input type="checkbox"/> A substitute specification.	
15.	<input type="checkbox"/> A change of power of attorney and/or address letter.	
16.	<input checked="" type="checkbox"/> Other items or information: Copy of PCT Application WO 01/15709, Sequence Listing, Diskette, Postcard, Check	

10/069623

17.	<p>■ The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 C.F.R. § 1.492(A)(1)-(5)):</p> <p>Neither international preliminary examination fee (37 C.F.R. § 1.482) nor international search fee (37 C.F.R. § 1.455(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1040.00</p> <p>International preliminary examination fee (37 C.F.R. § 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 890.00</p> <p>International preliminary examination fee (37 C.F.R. § 1.482) not paid to USPTO but international search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO \$ 740.00</p> <p>X International preliminary examination fee (37 C.F.R. § 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1) - (4) \$ 710.00 \$ 710.00</p> <p>International preliminary examination fee paid to USPTO (37 C.F.R. § 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00</p>		
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$ 710.00
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).			\$
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	[**] - 20 =		x \$18 \$
Independent claims	[**] - 3 =		x \$84 \$
Multiple dependent claims (if applicable)			+ \$280 \$
TOTAL OF ABOVE CALCULATIONS =			\$ 710.00
Reduction of 1/2 for filing by small entity, if applicable.			\$ 710.00/2 = \$ 355.00
SUBTOTAL =			\$ 355.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).			+ \$
TOTAL NATIONAL FEE =			\$
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property.			+ \$
TOTAL FEES ENCLOSED =			\$
			Amount to be refunded \$
			charged \$ 355.00
<p>■ a. A check in the amount of \$355.00 to cover the above fees is enclosed.</p> <p><input type="checkbox"/> b. Please charge my Deposit Account No. 03-2095 in the amount of \$ [**. **] to cover the above fees.</p> <p>■ c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095.</p>			
NOTE: Where an appropriate time limit under 37 C.F.R. §§ 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO:		 Signature Paul T. Clark Reg No. 30,162	
Paul T. Clark Clark & Elbing LLP 176 Federal Street Boston, MA 02110-2214 Telephone: 617-428-0200 Facsimile: 617-428-7045 Customer No.: 21559			

21559

PATENT TRADEMARK OFFICE



RECEIVED
DI07 REC'D PCT/PTO UP FEB 2003 #5

PATENT
ATTORNEY DOCKET NO. 06727/010002

Certificate of Mailing: Date of Deposit: January 29, 2003

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Kathy Meuse
Printed name of person mailing correspondence

Kathy Meuse
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Robert A. Murgita et al.	Art Unit:	Not Yet Assigned
Serial No.:	<u>10/069,623</u>	Examiner:	Not Yet Assigned
Filed:	February 26, 2002	Customer No.:	21559
Title:	USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS		

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows.

In the Specification:

Please insert the following after the title.

--Cross Reference To Related Applications

This application claims priority under 35 U.S.C. § 371 to PCT Application
PCT/US00/24129, filed September 1, 2000, which claims priority from United States Provisional
Application No. 60/152,166, filed September 2, 1999.--

If there are any additional charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: January 29, 2003

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Susan M. Michaud
Paul T. Clark Susan M. Michaud
Reg. No. 30,162 Reg. No. 42,885



21559

PATENT TRADEMARK OFFICE

41PRTS

101069623
JC18 Rec'd PCT/PTO 26 FEB 2002

WO 01/15709

PCT/US00/24129

USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS

BACKGROUND OF THE INVENTION

5 The invention related to methods of inhibiting apoptosis.

There are two general ways in which cells die. The most easily recognized way is by necrosis, which is usually caused by an injury that is severe enough to disrupt cellular homeostasis. Typically, the cell's osmotic pressure is disturbed and, consequently, the cell swells and then ruptures.

10 When the cellular contents are spilled into the surrounding tissue space, an inflammatory response often ensues.

The second general way by which cells die is referred to as apoptosis, or programmed cell death. Apoptosis often occurs so rapidly that it is difficult to detect. This may help to explain why the involvement of
15 apoptosis in a wide spectrum of biological processes has only recently been recognized.

The apoptosis pathway has been highly conserved throughout evolution, and plays a critical role in embryonic development, viral pathogenesis, cancer, autoimmune disorders, and neurodegenerative disease.

20 For example, inappropriate apoptosis may cause or contribute to AIDS, Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), retinitis pigmentosa and other diseases of the retina, myelodysplastic syndrome (e.g. aplastic anemia), toxin-induced liver disease, including alcoholism, and ischemic injury (e.g. myocardial infarction, stroke, and
25 reperfusion injury). Conversely, the failure of an apoptosis response has been implicated in the development of cancer, particularly follicular lymphoma, p53-mediated carcinomas, and hormone-dependent tumors, in autoimmune

disorders, such as lupus erythematosus and multiple sclerosis, and in viral infections, including those associated with herpes virus, poxvirus, and adenovirus.

5 In patients infected with HIV-1, mature CD4⁺ T lymphocytes respond to stimulation from mitogens or super-antigens by undergoing apoptosis. However, the great majority of these cells are not infected with the virus. Thus, inappropriate antigen-induced apoptosis could be responsible for the destruction of this vital part of the immune system in early stages of HIV infection.

10

SUMMARY OF THE INVENTION

In general, the invention features the inhibition of apoptosis in a cell, e.g., a cell in a mammal such as a human patient, by contacting the cell with recombinant alpha-fetoprotein ("rHuAFP") or an effective fragment thereof, or
15 with nucleic acid encoding rHuAFP. The invention, in inhibiting apoptosis, can provide therapy for diseases in which inappropriate apoptosis is a feature, including AIDS or HIV infection, neurodegenerative diseases such as ALS, a myelodysplastic syndrome, or an ischemic injury such as occurs in stroke, myocardial infarction, reperfusion injury, or a toxin-induced liver disease.
20 Other features and advantages of the invention will be apparent from the detailed description of the invention, the drawings, and the claims.

BRIEF SUMMARY OF THE DRAWINGS

Fig. 1 is the nucleotide sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) of the cDNA encoding human alpha-
25 fetoprotein, and the amino acid sequences (SEQ ID NOs: 3-8) of rHuAFP fragments.

Fig. 2 is the SDS-PAGE analysis of rHuAFP Fragment I (SEQ ID NO: 8) (Lane A, MW marker; Lane B, native human alpha-fetoprotein (AFP); Lane C, unpurified rAFP; Lane D, rAFP Fragment I, and Lane E, AFP (amino acids 1-590 of Fig. 1, SEQ ID NO: 2).

5

DETAILED DESCRIPTION OF THE INVENTION

Production of Recombinant Human Alpha-fetoprotein

Recombinant AFP can be produced in any standard recombinant protein production system, including prokaryotic cells such as *E. coli*, and eukaryotic systems such as yeast, mammalian (e.g., CHO cells) and insect cells.

10 Prokaryotic production of rHuAFP is described in Murgita U.S. Patent No. 5,384,250, hereby incorporated by reference.

The methods of the invention can also employ biologically active fragments of rHuAFP. A biologically active fragment of rHuAFP is one that possesses at least one of the following activities: (a) directs a specific
15 interaction with a target cell, e.g., binds to a cell expressing a receptor that is recognized by rHuAFP (e.g., the membrane of a cancer cell such as MCF-7); or (b) halts, reduces, or inhibits apoptosis (e.g., binds to a cell surface receptor and imparts an anti-apoptosis signal). The ability of rHuAFP fragments to bind to a receptor which is recognized by rHuAFP can be tested using any
20 standard binding assay known in the art.

In general, fragments of rHuAFP are produced according to the techniques of polypeptide expression and purification described in U.S. Patent No. 5,384,250. DNA sequences encoding fragments of rHuAFP can be generated by standard techniques and cloned into expression vectors for
25 expression in recombinant cells. Expressed fragments can be isolated by various chromatographic and/or immunological methods known in the art.

Lysis and fractionation of rHuAFP-containing cells prior to affinity chromatography may be performed by standard methods. Once isolated, the recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques
5 In Biochemistry and Molecular Biology, Work and Burdon, eds., Elsevier, 1980).

Recombinant HuAFP fragments can be assayed by immunological procedures, such as Western blot, immunoprecipitation analysis of recombinant cell extracts, or immunofluorescence (using, e.g., the methods
10 descrbed in Ausubel et al., *Current Protocols In Molecular Biology*, Greene Publishing Associates and Wiley Interscience (John Wiley & Sons), New York, 1994).

Useful rHuAFP fragments preferably have at least 20 contiguous amino acids, preferably at least 50 contiguous amino acids, more preferably at
15 least 100 contiguous amino acids, and most preferably at least 200 to 400 or more contiguous amino acids in length.

Recombinant HuAFP fragments of interest include, but are not limited to, Domain I (amino acids 1 (Thr) - 197 (Ser), see Fig. 1, SEQ ID NO: 3), Domain II (amino acids 198(Ser) - 389 (Ser), see Fig. 1, SEQ ID NO: 4),
20 Domain III (amino acids 390 (Gln) - 590 (Val), see Fig. 1, SEQ ID NO: 5), Domain I+II (amino acids 1 (Thr) - 389 (Ser), see Fig. 1, SEQ ID NO: 6), Domain II+III (amino acids 198 (Ser) - 590 (Val), see Fig. 1, SEQ ID NO: 7), and rHuAFP Fragment I (amino acids 266 (Met) - 590 (Val), see Fig. 1, SEQ ID NO: 8).

25 By "inhibiting apoptosis" is meant a decrease in the number of cells which undergo apoptosis relative to an untreated control. Preferably, the decrease is at least 25%, more preferably the decrease is 50%, and most

preferably the decrease is at least one-fold.

Apoptosis Assays

- Apoptosis assays are described in the following references. Assays for apoptosis in lymphocytes are disclosed by, for example: Li et al.,
- 5 "Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein", Science 268:429-431, 1995; Gibellini et al., "Tat-expressing Jurkat cells show an increased resistance to different apoptosis stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection", Br. J. Haematol. 89:24-33, 1995; Martin et al., "HIV-1 infection of human CD4⁺ T cells *in vitro*.
 - 10 Differential induction of apoptosis in these cells." J. Immunol. 152:330-42, 1994; Terai et al., "Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1", J. Clin Invest. 87:1710-5, 1991; Dhein et al., "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) 11, Nature 373:438-441, 1995; Katsikis et al., "Fas antigen stimulation induces
 - 15 marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals", J. Exp. Med. 181:2029-2036, 1995; Estendorp et al., "Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120", Nature 375:497, 1995; DeRossi et al., Virology 198:234-44, 1994.

- Assays for apoptosis in fibroblasts are disclosed by, for example:
- 20 Vossbeck et al.; "Direct transforming activity of TGF-beta on rat fibroblasts," Int. J. Cancer 61:92-97, 1995; Goruppi et al., "Dissection of c-myc domains involved in S phase induction of NIH3T3 fibroblasts," Oncogene 9:1537-44, 1994; Fernandez et al., "Differential sensitivity of normal and Ha-ras transformed C3H mouse embryo fibroblasts to tumor necrosis factor: induction
 - 25 of bcl-2, c-myc, and manganese superoxide dismutase in resistant cells," Oncogene 9:2009-17, 1994; Harrington et al., "c-Myc-induced apoptosis in

fibroblasts is inhibited by specific cytokines," EMBO J., 13:3286-3295, 1994;
Itoh et al., "A novel protein domain required for apoptosis. Mutational
analysis of human Fas antigen," J. Biol. Chem. 268:10932-7, 1993.

Assays for apoptosis in neuronal cells are disclosed by, for example:

- 5 Melino et al., "Tissue transglutaminase and apoptosis: sense and antisense
transfection studies with human neuroblastoma cells," Mol. Cell Biol.
14:6584-6596, 1994; Rosenbaum et al., "evidence for hypoxia-induced,
programmed cell death of cultured neurons," Ann. Neurol. 36:864-870, 1994;
Sato et al., "Neuronal differentiation of PC12 cells as a result of prevention of
10 cell death by bcl-2," J. Neurobiol. 25:1227-1234, 1994; Ferrari et al., "N-
acetylcysteine D- and L-stereoisomers prevents apoptosis death of neuronal
cells," J. Neurosci. 15:2857-2866, 1995; Talley et al., "Tumor necrosis
factor alpha-induced apoptosis in human neuronal cells: protection by the
antioxidant N-acetylcysteine and the genes bcl-2 and crmA," Mol. Cell Biol.
15 1585:2359-2366, 1995; Talley et al., "Tumor Necrosis Factor Alpha-Induced
Apoptosis in Human Neuronal Cells: Protection by the Antioxidant
N-Acetylcysteine and the Genes bcl-2 and crmA," Mol. Cell. Biol. 15:2359-
2366, 1995; and Walkinshaw et al., "Induction of apoptosis in
catecholaminergic PC12 cells by L-DOPA. Implication for the treatment of
20 Parkinson's disease," J. Clin. Invest. 95:2458-2464, 1995.

- Assays for apoptosis in insect cells are disclosed by, for example:
- Clem et al., "Prevention of apoptosis by a baculovirus gene during infection of
insect cells," Science 254:1388-90, 1991; Crook et al., "An apoptosis-
inhibiting baculovirus gene with a zinc finger-like motif," J. Virol. 67:2168-
25 74, 1993; Rabizadeh et al., "Expression of the baculovirus p35 gene inhibits
mammalian neural cell death," J. Neurochem. 61:2318-21, 1993; Birnbaum et
al., "an apoptosis inhibiting gene from a nuclear polyhedrosis virus encoding a

polypeptide with Cys/His sequence motifs," J. Virol. 68:2521-8, 1994; and Clem et al., "Control of programmed cell death by the baculovirus genes p35 and IAP," Mol. Cell. Biol. 14:5212-5222, 1994.

Gene Therapy

- 5 rHuAFP-encoding genes can be used according to the invention in anti-apoptosis gene therapy. In particular, a functional rHuAFP gene may be used to sustain neuronal cells that undergo apoptosis in the course of a neurodegenerative disease; lymphocytes (i.e., T cells and B cells); or cells that have been injured by ischemia.
- 10 Retroviral vectors, adenoviral vectors, adeno-associated viral vectors, or other viral vectors with the appropriate tropism for cells likely to be involved in apoptosis (for example, epithelial cells) may be used as a gene transfer delivery system for a therapeutic rHuAFP gene construct. Numerous vectors useful for this purpose are known (Miller, Human Gene Therapy 15-15, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis and Anderson, BioTechniques 6:608-614, 1988; Tolstoshev and Anderson, Current Opinion in Biotechnology 1:55-61, 1990; Sharp, The Lancet 337:1277-1278, 1991; Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987; Anderson, Science 226:401-409, 1984; Moen, Blood Cells 17:407-416, 20 1991; Miller et al., Biotechniques 7:980-990, 1989; Le Gal La Salle et al., Science 259:988-990, 1993; and Johnson, Chest 107:77S-83S, 1995).
- 25 Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U.S. Patent NO. 5,399,346). Non-viral approaches may also be employed for the introduction of therapeutic DNA into cells otherwise predicted to undergo apoptosis. For example rHuAFP may be introduced into a neuron or a

T cell by lipofection (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987; Ono et al., Neurosci. Lett. 117:259, 1990; Brigham et al., Am. J. Med. Sci. 298:278, 1989; Staubinger et al., Meth. Enz. 101:512, 1983), asialorosonucoid-polylysine conjugation (Wu et al., J. Biol. Chem. 263:14621, 5 1988; Wu et al., J. Biol. Chem. 264:16985, 1989); or, less preferably, microinjection under surgical conditions (Wolff et al., Science 247:1465, 1990).

For any of the methods described above, the therapeutic rHuAFP DNA construct is preferably applied to the site of the predicted apoptosis event 10 (for example, by injection), or to tissue in the vicinity of the predicted apoptosis event, or to a blood vessel supplying the cells predicted to undergo apoptosis.

rHuAFP expression can be directed from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or 15 metallothionein promoters), and regulated by any appropriate mammalian regulatory element. For example, if desired, enhancers that preferentially direct gene expression in neural cells, T cells, or B cells may be used to direct rHuAFP expression. Alternatively, if an rHuAFP genomic clone is used in a therapeutic construct, regulation may be mediated by the cognate regulatory 20 sequences or, if desired, by regulatory sequences derived from a heterologous source, including any of the promoters or regulatory elements described above.

Alternatively, rHuAFP gene therapy is accomplished by direct administration of the rHuAFP mRNA or antisense rHuAFP mRNA to a cell that is expected to undergo apoptosis. The mRNA may be produced and 25 isolated by any standard technique, but is most readily produced by *in vitro* transcription using an rHuAFP cDNA under the control of a high efficiency promoter (e.g., the T7 promoter). Administration of rHuAFP mRNA to cells

can be carried out by any of the methods for direct nucleic acid administration described below.

Ideally, the production of rAFP protein by any gene therapy approach will result in cellular levels of rAFP that are at least equivalent to the normal, cellular level of rHuAFP in an unaffected cell. Treatment by any rHuAFP-mediated gene therapy approach may be combined with more traditional therapies.

Administration of rAFP Polypeptides

Another therapeutic approach of the invention involves administration of recombinant rHuAFP, either directly to the site of a predicted apoptosis event (for example, by injection) or systemically (for example, by any conventional recombinant protein administration technique). The dosage of rHuAFP depends on a number of factors, including the size and health of the individual patient, but, generally, between 0.1 mg and 100 mg are administered per day to an adult in a pharmaceutically-acceptable formulation. Administration may begin before or after the patient is symptomatic. Any appropriate route of administration may be employed, for example, administration may be parenteral, intravenous, intraarterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral. Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasals drops, or aerosols.

Methods well known in the art of making formulations are found, for example, in *Remington's Pharmaceutical Sciences*, (18th edition), ed. A.

Gennaro, 1990, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of rHuAFP.

Treatment with an rHuAFP protein or gene may be combined with more traditional therapies for the disease such as surgery, steroid therapy, or chemotherapy for autoimmune disease; antiviral therapy for AIDS; and tissue plasminogen activator (TPA) for ischemic injury.

Other Embodiments

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.

What is claimed is:

1. A method of inhibiting apoptosis in a cell, said method comprising administering to said cell an apoptosis inhibiting amount of rHuAFP or an apoptosis-inhibiting fragment thereof.
2. The method of claim 1, wherein said cell is in a mammal.
- 5 3. The method of claim 2, wherein said mammal is human.
4. The method of claim 3, wherein said human is infected with HIV, or has a neurodegenerative disease, a myelodysplastic syndrome, or an ischemic injury.
5. The method of claim 4, wherein said ischemic injury is
10 caused by a myocardial infarction, a stroke, a reperfusion injury, or a toxin-induced liver disease.
6. A method of inhibiting apoptosis in a cell, said method comprising transfecting said cell with nucleic acid encoding rHuAFP or an apoptosis-inhibiting fragment thereof.
- 15 7. The method of claim 6, wherein said cell is in a human patient.
8. The method of claim 7, wherein said human patient is infected with HIV, or has a neurodegenerative disease, a myelodysplastic syndrome, or an ischemic injury.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15709 A1

- (51) International Patent Classification⁷: **A61K 31/7088**,
38/38, C12N 5/00, 15/85 Cambridge, MA 02138 (US). LINDSAY, Stace [US/US];
8 Cypress Street, Cambridge, MA 02140 (US).
- (21) International Application Number: PCT/US00/24129 (74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Fed-
eral Street, Boston, MA 02110-2214 (US).
- (22) International Filing Date:
1 September 2000 (01.09.2000) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/152,166 2 September 1999 (02.09.1999) US (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/152,166 (CIP)
Filed on 2 September 1999 (02.09.1999)
- (71) Applicant (*for all designated States except US*): AT-
LANTIC BIOPHARMACEUTICALS, INC. [US/US];
50 Church Street, Cambridge, MA 02138 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): MURGITA, Robert,
A. [US/CA]; 17 Parkside Place, Montreal, Quebec H3H
1A7 (CA). MULROY, Robert [US/US]; 19 Hilliard Street,

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS

(57) Abstract: A method of inhibiting apoptosis in a cell by administering to the cell an apoptosis inhibiting amount of recombinant human alpha-feta protein or an apoptosis-inhibiting fragment thereof.

WO 01/15709 A1

AT (2)
 -1
 met lys trp val glu ser ile phe leu leu asn phe thr glu ser arg
 -10
 ATG AAG TGG GTG GAA TCA ATT TTT TTA ATT TTC CTA AAT TTT ACT GAA TCC AGA (101)
 ATTGTGCTTCCACCACCTGCCAATAACAAATACTAGCAACC
 1 thr leu his arg asn glu tyr gly ile ala ser ile leu asp ser tyr gln cys thr ala glu ile ser leu ala asp leu ala thr ile
 20
 ACA CTG CAT AGA AAT GAA TAT GGA ATA GCT TCC ATA TTG GAT TCT TAC CAA TGT ACT GCA GAG ATA AGT TTA GCT GAC CTG GCT ACC ATA (191)
 30
 31 phe phe ala gln phe val gln glu ala thr tyr lys glu val ser lys met val lys asp ala leu thr ala ile glu lys pro thr gly
 50
 TTT TTT GCC CAG TTT GTT CAA GAA GCC ACT TAC AAG GAA GTA AGC AAA ATG GTG AAA GAT GCA TTG ACT GCA ATT GAG AAA CCC ACT GGA (281)
 60
 61 asp glu gln ser ser gly cys leu glu asn gln leu pro ala phe leu glu glu leu cys his glu lys glu ile leu glu lys tyr gly
 80
 GAT GAA GAG TCT TCA GGG TGT TTA GAA AAC CAG CTA CCT GCC TTT CTG GAA GAA CTT TGC CAT GAG AAA GAA ATT TTG GAG AAG TAC GGA (371)
 90
 91 his ser asp cys cys ser gln ser glu glu gly arg his asn cys phe leu ala his lys lys pro thr pro ala ser ile pro leu phe
 110
 CAT TCA GAC TGC TGC AGC CAA AGT GAA GAG GGA AGA CAT AAC TGT TTT CTT GCA CAC AAA AAG CCC ACT CCA GCA TCG ATC CCA CTT TTC (461)
 120
 121 gln val pro glu pro val thr ser cys glu ala tyr glu glu asp arg glu thr phe met asn lys phe ile tyr glu ile ala arg arg
 140
 CAA GTT CCA GAA CCT GTC ACA AGC TGT GAA GCA TAT GAA GAA GAC AGG GAG ACA TTC ATG AAC AAA TTC ATT TAT GAG ATA GCA AGA AGG (551)
 150
 151 his pro phe leu tyr ala pro thr ile leu leu trp ala ala arg tyr asp lys ile ile pro ser cys cys lys ala glu asn ala val
 170
 CAT CCC TTC CTG TAT GCA CCT ACA ATT CTT TGG GCT GCT CGC TAT GAC AAA ATA ATT CCA TCT TGC TGC AAA GCT GAA AAT GCA GTT (641)
 180
 190 glu cys phe gln thr lys ala ala thr val thr lys glu leu arg glu ser ser leu leu asn gln his ala cys ala val met lys asn
 210
 GAA TGC TTC CAA ACA AAG GCA ACA GTT ACA AAA GAA TTA AGA GAA AGC AGC TTG TTA AAT CAA CAT GCA TGT GCA GTA ATG AAA AAT (731)

Fig. 1

211 phe gly thr arg thr phe gln ala ile thr val thr lys leu ser gln lys phe thr lys val asn phe thr glu ile gln lys leu val (821)
 TTT GGG ACC CGA ACT TTC CAA GCC ATA ACT GTT ACT AAA CTG ACT CAG AAG TTT ACC AAA GTT AAT TTT ACT GAA ATC CAG AAA CTA GTC
 220
 241 leu asp val ala his val his glu his cys cys arg gly asp val leu asp cys leu gln asp gly glu lys ile met ser tyr ise cys
 CTG GAT GTG GCC CAT GTA CAT GAG CAC TGT TGC AGA GGA GAT GTG CTG GAT TGT CTG CAG GAT GGG GAA AAA ATC ATG TCC TAC ATA TGT
 250
 271 ser gln gln asp thr leu ser asn lys ile thr glu cys cys lys leu thr thr leu glu arg gly gln cys ile ile his ala glu asn
 TCT CAA CAA GAC ACT CTG TCA AAC AAA ATA ACA GAA TGC TGC AAA CTG ACC AGC CTG GAA CGT GGT CAA TGT ATA ATT CAT GCA GAA AAT(1001)
 280
 301 asp glu lys pro glu gly leu ser pro asn leu asn arg phe leu gly asp arg phe asn gln phe ser ser gly glu lys asn ile
 GAT GAA AAA CCT GAA GGT CTA TCT CCA AAT CTA AAC AGG TTT TTA GGA GAT AGA GAT TTT AAC CAA TTT TCT TCA GGG GAA AAA AAT ATC(1091)
 310
 331 phe leu ala ser phe val his glu tyr ser arg arg his pro gln leu ala val ser val ile leu arg val ala lys gly tyr gln glu
 TTC TTG GCA AGT TTT GTT CAT GAA TAT TCA AGA AGA CAT CCT CAG CTT GCT GTC TCA CTA ATT CTA AGA GTT GCT AAA GGA TAC CAG GAG(1181)
 340
 361 leu glu lys cys phe gln thr glu thr glu asn pro leu glu cys gln asp lys gly glu glu leu gln lys tyr ile gln glu ser gln
 TTA TTG GAG AAG TGT TTC CAG ACT GAA AAC CCT CTT GAA TGC CAA GAT AAA GGA GAA GAA TTA CAG AAA TAC ATC CAG GAG AGC CAA(1271)
 370
 391 ala leu ala lys arg ser cys gly leu phe gln lys leu gly glu tyr tyr leu gln asn ala phe leu val ala tyr thr lys lys ala
 GCA TTG GCA AAG CGA AGC TGC TGC CTC TTC CAG AAA CTA GGA GAA TAT TAC TTA CAA AAT GCG TTT CTC GTT GCT TAC ACA AAG AAA GCC(1361)
 400
 421 pro gln leu thr ser ser glu leu met ala ile thr arg lys met ala ala thr ala thr cys cys gln leu ser glu asp lys leu
 CCC CAG CTG ACC TCG GAG CTG ATG GCC ATC ACC AGA AAA ATG GCA GCC ACA GCA GCC ACT TGT TGC CAA CTC AGT GAG GAC AAA CTA(1451)
 430
 450

Fig. 1 (CONTINUED)

10/069623

451	460	470	480
leu ala cys gly glu gly ala ala asp ile ile ile gly his leu cys ile arg his glu met thr pro val asn pro gly val gly gln			
TTTG GCC TGT GGC GAG GGA GCG GCT GAC ATT ATT ATC GGA CAC TTA TGT ATC AGA CAT GAA ATG ACT CCA GTA AAC CCT GGT GTT GGC CAG(1541)			
481	490	500	510
cys cys thr ser ser tyr ala asn arg arg pro cys phe ser ser leu val val asp glu thr tyr val pro pro ala phe ser asp asp			
TGC TGC ACT TCT TCA TAT GCC AAC AGG AGG CCA TGC TTC AGC AGC TTG GTG GAT GAA ACA TAT GTC CCT CCT GAT GAC(1631)			
511	520	530	540
lys phe ile phe his lys asp leu cys gln ala gln gly val ala leu gln thr met lys gln glu phe leu ile asn leu val lys gln			
AAG TTC ATT TTC CAT AAG GAT CTG TGC CAA GGT CAG GGT GTA GCG CTG CAA ACG ATG AAG CAA GAG TTT CTC ATT AAC CTT GTG AAG CAA(1721)			
541	550	560	570
lys pro gln ile thr glu glu gln leu glu ala val ile ala asp phe ser gly leu leu glu lys cys cys gln gly gln glu gln glu			
AAG CCA CAA ATA ACA GAG GAA CAA CTT GAG GCT GTC ATT GCA GAT TTC TCA GGC CTG TTG GAG AAA TGC TGC CAA GGC CAG GAA CAG GAA(1811)			
571	580	590	
val cys phe ala glu glu gly gln lys leu ile ser lys thr arg ala ala leu gly val ter			
GTC TGC TTT GCT GAA GAG GGA CAA AAA CTG ATT TCA AAA ACT CGT GCT GCT TTG GGA GTT TAA			
			ATTACTTCAGGGGAGAGACAAACAGGTCT(1908)
TTCAATCGGTGTGAACCTTTCTCTTTAATTTAACTGATTTAACCTTTTGTGTAATTAATGAAATGATAAGACTTTTATGTGAGATTTCTTATACAGAAATAAAATATCTCCAAA(2027)			

Fig. 1 (CONTINUED)




Fig. 2

PATENT

ATTORNEY DOCKET NO: 06727/010002

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled USE OF RAFP TO INHIBIT OR PREVENT APOPTOSIS, the specification of which

~ is attached hereto.

: was filed on February 26, 2002 as Application Serial No. 10/069,623
and was amended on _____.

~ was described and claimed in PCT International Application No.
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, § 1.56.

FOREIGN PRIORITY RIGHTS: I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
PCT	PCT/US00/24129	September 1, 1999	Yes/No

PROVISIONAL PRIORITY RIGHTS: I hereby claim priority benefits under Title 35, United States Code, § 119(e) and § 120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status
60/152,166	September 2, 1999	Pending



Dec-10-02 17:09

From-CLARK & ELBING LLP

617-237-1558

T-067 P.003/004 F-970

NON-PROVISIONAL PRIORITY RIGHTS: I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status

I hereby appoint the following attorney and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bleker-Brady, Ph.D. Reg. No. 39,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, James D. DeCamp, Ph.D., Reg. No. 43,580, Sean J. Edman, Reg. No. 42,505, Vicki Healy, Reg. No. 48,343.

Address all telephone calls to: Paul T. Clark at 617/428-0200.

Address all correspondence to: Paul T. Clark at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110. Customer No: 21559

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Robert A. Murgita	Montreal, Quebec H3H 1A7, CANADA	17 Parkside Place Montreal, Quebec H3H 1A7 CANADA	U.S.A.
Signature: <i>R. A. Murgita</i>			Date: Dec. 10, 2002

Nov-12-02 12:41

From-CLARK & ELBING LLP

617-237-1888

T-575 P.004/004 F-382

COMBINED DECLARATION AND POWER OF ATTORNEY


200

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Robert Mulroy	Cambridge, Massachusetts USA MA	18 Hilliard Street Cambridge, Massachusetts 02138 USA	U.S.A.
Signature: <i>Robert Mulroy</i>			Date: 11/12/02

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Stace Lindsay	Cambridge, Massachusetts USA	8 Cypress Street Cambridge, Massachusetts 02140 USA	U.S.A.
Signature:			Date:

COMBINED DECLARATION AND POWER OF ATTORNEY

	Massachusetts USA	Cambridge, Massachusetts 02138 USA	
Signature:			Date:

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Stace Lindsay	Cambridge, Massachusetts USA MA	8 Cypress Street Cambridge, Massachusetts 02140 USA	U.S.A.
Signature: 			Date: 11/21/02

WO 01/15709

SEQUENCE LISTING

<110> Atlantic Biopharmaceuticals, Inc.
Murgita, Robert A.
Mulroy, Robert
Lindsay, Stace

<120> USE OF rAFP TO INHIBIT OR PREVENT
APOPTOSIS

<130> 06727/010W02

<150> US 60/152,166

<151> 1999-09-02

<160> 8

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2027

<212> DNA

<213> Homo sapiens

<400> 1
atattgtgct tccaccactg ccaataacaa aataactagc aaccatgaag tgggtggaat 60
caattttttt aattttccta cttaaatttta ctgaatccag aacactgcat agaaatgaat 120
atggaatagc ttccatattg gattcttacc aatgtactgc agagataagt ttagctgacc 180
tggctaccat attttttgcc cagtttggtc aagaagccac ttacaaggaa gtaagcaaaa 240
tggtgaaaga tgcattgact gcaattgaga aaccactgg agatgaacag tcttcagggt 300
gtttagaaaa ccagctacct gcctttctgg aagaactttg ccatgagaaa gaaattttgg 360
agaagtacgg acattcagac tgctgcagcc aaagtgaaga ggggaagacat aactgttttc 420
ttgcacacaa aaagccact gcagcatgga tccactttt ccaagttcca gaacctgtca 480
caagctgtga agcatatgaa gaagacaggg agacattcat gaacaaattc atttatgaga 540
tagcaagaag gcateccctc ctgtatgcac ctacaattct tctttcggct gctgggtatg 600
agaaaataat tccatcttgc tgcaaagctg aaaatgcagt tgaatgcttc caaacaaggg 660
cagcaacagt tacaaaagaa ttaagagaaa gcagcttggt aaatcaacat gcattgtccag 720
taatgaaaaa ttttgggacc cgaactttcc aagccataac tgttactaaa ctgagtcaga 780
agtttaccac agttaatttt actgaaatcc agaaactagt cctggatgtg gcccatgtac 840
atgagcactg ttgcagagca gatgtgctgg attgtctgca ggatggggaa aaaatcatgt 900
cctacatatg ttctcaacaa gacactctgt caaacaattc aacagaatgc tgcaaactga 960
ccacgctgga acgtggtcaa tgtataattc atgcagaaaa tgatgaaaaa cctgaagggtc 1020
tatctccaaa tctaaacagg tttttaggag atagagattt taaccaattt tcttcagggg 1080
aaaaaaatat cttcttgcca agttttgttc atgaatattc aagaagacat cctcagcttg 1140
ctgtctcagt aattctaaga gttgctaaag gataccagga gttattggag aagtgtttcc 1200
agactgaaaa ccctcttgaa tgccaagata aaggagaaga agaattacag aaatacatcc 1260
aggagagcca agcattggca aagcgaagct gcggcctctt ccagaaacta ggagaatatt 1320
acttacaaaa tgagtttctc gttgtttaca caaagaaagc cccccagctg acctcgctgg 1380
agctgatggc catcaccaga aaaatggcag ccacagcagc cacttggtgc caactcagtg 1440
aggacaaact attggcctgt ggcgagggag cggctgacat tattatcgga cacttatgta 1500
tcagacatga aatgactcca gtaaaccttg gtgttgacca gtgctgcact tcttcatatg 1560
ccaacaggag gccatgcttc agcagcttgg tgggtggatga aacatatgtc cctcctgcat 1620
tctctgatga caagttcatt ttccataagg atctgtgcca agctcagggt gttagcgtgc 1680

WO 01/15709

PCT/US00/24129

```

aaaggatgaa gcaagagttt ctcattaacc ttgtgaagca aaagccacaa ataacagagg 1740
aacaacttga ggctctcatt gcagatttct caggcctggt ggagaaatgc tgccaaggcc 1800
aggaacagga agtctgcttt gctgaagagg gacaaaaact gatttcaaaa actggtgctg 1860
ctttgggagt ttaaattact tcaggggaag agaagacaaa acgagtcctt cattcggtgt 1920
gaacttttct ctttaatttt aactgattta acactttttg tgaattaatg aaatgataaa 1980
gacttttatg tgagatttcc ttatcacaga aataaaatat ctccaaa 2027

```

<210> 2

<211> 590

<212> PRT

<213> Homo sapiens

<400> 2

```

Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
1      5      10      15
Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
20      25      30
Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
35      40      45
Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
50      55      60
Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
65      70      75      80
His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
85      90      95
Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro
100     105     110
Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
115     120     125
Cys Glu Ala Tyr Glu Gln Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
130     135     140
Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro Thr Ile Leu
145     150     155     160
Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
165     170     175
Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
180     185     190
Glu Leu Arg Glu Ser Ser Leu Leu Asn Gln His Ala Cys Pro Val Met
195     200     205
Lys Asn Phe Gly Thr Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu
210     215     220
Ser Gln Lys Phe Thr Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val
225     230     235     240
Leu Asp Val Ala His Val His Glu His Cys Cys Arg Ala Asp Val Leu
245     250     255
Asp Cys Leu Gln Asp Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln
260     265     270
Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr
275     280     285
Leu Glu Arg Gly Gln Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro
290     295     300
Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe
305     310     315     320
Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val

```

WO 01/15709

PCT/US00/24129

```

                325                330                335
His Glu Tyr Ser Arg Arg His Pro Gln Leu Ala Val Ser Val Ile Leu
                340                345                350
Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr
                355                360                365
Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys
                370                375                380
Tyr Ile Gln Glu Ser Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe
385                390                395                400
Gln Lys Leu Gly Glu Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr
                405                410                415
Thr Lys Lys Ala Pro Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr
                420                425                430
Arg Lys Met Ala Ala Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp
                435                440                445
Lys Leu Leu Ala Cys Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His
                450                455                460
Leu Cys Ile Arg His Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln
465                470                475                480
Cys Cys Thr Ser Ser Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu
                485                490                495
Val Val Asp Glu Thr Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe
                500                505                510
Ile Phe His Lys Asp Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg
                515                520                525
Met Lys Gln Glu Phe Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile
                530                535                540
Thr Glu Glu Gln Leu Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu
545                550                555                560
Glu Lys Cys Cys Gln Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu
                565                570                575
Gly Gln Lys Leu Ile Ser Lys Thr Gly Ala Ala Leu Gly Val
                580                585                590

```

<210> 3
 <211> 197
 <212> PRT
 <213> Homo sapiens

```

<400> 3
Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
 1                5                10                15
Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
                20                25                30
Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
                35                40                45
Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
                50                55                60
Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
65                70                75                80
His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
                85                90                95
Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro

```

PCT/US00/24129

```
<210> 4
<211> 192
<212> PRT
<213> Homo sapiens
```

```
<210> 5
<211> 201
<212> PRT
<213> Homo sapiens
```

-4-

WO 01/15709

PCT/US00/24129

Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu
 1 5 10 15
 Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr Thr Lys Lys Ala Pro
 20 25 30
 Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala
 35 40 45
 Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys
 50 55 60
 Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His Leu Cys Ile Arg His
 65 70 75 80
 Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser
 85 90 95
 Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu Val Val Asp Glu Thr
 100 105 110
 Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe Ile Phe His Lys Asp
 115 120 125
 Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe
 130 135 140
 Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile Thr Glu Glu Gln Leu
 145 150 155 160
 Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln
 165 170 175
 Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile
 180 185 190
 Ser Lys Thr Gly Ala Ala Leu Gly Val
 195 200

<210> 6

<211> 389

<212> PRT

<213> Homo sapiens

<400> 6

Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
 1 5 10 15
 Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
 20 25 30
 Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
 35 40 45
 Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
 50 55 60
 Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
 65 70 75 80
 His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
 85 90 95
 Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro
 100 105 110
 Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
 115 120 125
 Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
 130 135 140
 Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro Thr Ile Leu
 145 150 155 160

WO 01/15709

PCT/US00/24129

```

Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
      165                      170                      175
Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
      180                      185                      190
Glu Leu Arg Glu Ser Ser Leu Leu Asn Gln His Ala Cys Pro Val Met
      195                      200                      205
Lys Asn Phe Gly Thr Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu
      210                      215                      220
Ser Gln Lys Phe Thr Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val
      225                      230                      235                      240
Leu Asp Val Ala His Val His Glu His Cys Cys Arg Ala Asp Val Leu
      245                      250                      255
Asp Cys Leu Gln Asp Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln
      260                      265                      270
Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr
      275                      280                      285
Leu Glu Arg Gly Gln Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro
      290                      295                      300
Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe
      305                      310                      315                      320
Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val
      325                      330                      335
His Glu Tyr Ser Arg Arg His Pro Gln Leu Ala Val Ser Val Ile Leu
      340                      345                      350
Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr
      355                      360                      365
Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys
      370                      375                      380
Tyr Ile Gln Glu Ser
      385

```

<210> 7

<211> 393

<212> PRT

<213> Homo sapiens

<400> 7

```

Ser Leu Leu Asn Gln His Ala Cys Pro Val Met Lys Asn Phe Gly Thr
  1                      5                      10                      15
Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu Ser Gln Lys Phe Thr
      20                      25                      30
Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val Leu Asp Val Ala His
      35                      40                      45
Val His Glu His Cys Cys Arg Ala Asp Val Leu Asp Cys Leu Gln Asp
      50                      55                      60
Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser
      65                      70                      75                      80
Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln
      85                      90                      95
Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro
      100                      105                      110
Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser
      115                      120                      125

```

WO 01/15709

PCT/US00/24129

Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg
 130 135 140
 Arg His Pro Gln Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly
 145 150 155 160
 Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr Glu Asn Pro Leu Glu
 165 170 175
 Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys Tyr Ile Gln Glu Ser
 180 185 190
 Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu
 195 200 205
 Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr Thr Lys Lys Ala Pro
 210 215 220
 Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala
 225 230 235 240
 Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys
 245 250 255
 Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His Leu Cys Ile Arg His
 260 265 270
 Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser
 275 280 285
 Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu Val Val Asp Glu Thr
 290 295 300
 Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe Ile Phe His Lys Asp
 305 310 315 320
 Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe
 325 330 335
 Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile Thr Glu Glu Gln Leu
 340 345 350
 Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln
 355 360 365
 Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile
 370 375 380
 Ser Lys Thr Gly Ala Ala Leu Gly Val
 385 390

<210> 8

<211> 325

<212> PRT

<213> Homo sapiens


<400> 8

Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser Asn Lys Ile Thr
 1 5 10 15
 Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln Cys Ile Ile His
 20 25 30
 Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro Asn Leu Asn Arg
 35 40 45
 Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser Gly Glu Lys Asn
 50 55 60
 Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg Arg His Pro Gln
 65 70 75 80
 Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly Tyr Gln Glu Leu
 85 90 95

$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & -i \\ i & 1 \end{pmatrix}$

[illegible][illegible]

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

☒ **Scanned copy is best available.** Declaration pages 2 & 3 have
black line.